SCHEMBL3700860

SCHEMBL3700860

N#Cc1ccc(NC(=O)n2cc3ccccc3c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 4/20 0.58
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
RAB9A P51151 2/20 0.50
NPC1 O15118 1/20 0.50
MAPT P10636 3/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 3/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
NLRP3 Q96P20 1/20 0.47
FAAH O00519 1/20 0.47
TAS1R3 Q7RTX0 1/20 0.47
TAS1R1 Q7RTX1 1/20 0.47
TAS1R2 Q8TE23 1/20 0.47
KDM4E B2RXH2 2/20 0.46
SAE1 Q9UBE0 1/20 0.46
UBA2 Q9UBT2 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3704418 0.84 CYP2C9 (0.43) NAMPTMEN1KMT2ARAB9ANPC1
SCHEMBL3706029 0.79 MAOA (0.53) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL701869 0.79 TAS1R3 (0.55) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3709539 0.79 MAPT (0.50) NAMPTMEN1KMT2ARAB9ANPC1
SCHEMBL703043 0.79 TAS1R3 (0.55) NAMPTMEN1KMT2ARAB9ANPC1
SCHEMBL3710955 0.76 HDAC1 (0.37) NAMPTMEN1KMT2ARAB9ANPC1
SCHEMBL702786 0.75 TAS1R3 (0.58) MEN1KMT2ARAB9ANPC1MAPT
SCHEMBL3702945 0.75 HDAC1 (0.50) NAMPTRAB9ANPC1MAPTALDH1A1
SCHEMBL18184936 0.74 CYP19A1 (0.56) NAMPTMEN1KMT2ARAB9AMAPT
SCHEMBL3695389 0.74 NAMPT (1.00) NAMPTTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093624-B2 NAMPT and ROCK inhibitors ABBVIE INC. (US) 2018-10-09 US disclosed
US-9302989-B2 NAMPT and rock inhibitors ABBVIE INC. (US) 2016-04-05 US disclosed
US-20160031880-A1 Nampt and Rock Inhibitors ABBVIE INC. (US) 2016-02-04 US disclosed
EP-2640698-A1 NAMPT AND ROCK INHIBITORS AbbVie Inc. (US) 2013-09-25 EP disclosed
WO-2012067965-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-24 WO disclosed
US-20120122842-A1 NAMPT AND ROCK INHIBITORS ABBOTT LABORATORIES (US) 2012-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093624-B2 NAMPT and ROCK inhibitors NAMPT, NNMT, NADK NAMPT 1/4885MEN1 1333/4885KMT2A 1248/4885
US-20120122842-A1 NAMPT AND ROCK INHIBITORS NAMPT, NNMT, NME2 NAMPT 1/4885MEN1 1139/4885KMT2A 2025/4885
US-20160031880-A1 Nampt and Rock Inhibitors NAMPT, NNMT, NME2 NAMPT 1/4885MEN1 1139/4885KMT2A 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.